Overview

Randomized Controlled Trial in Patients on Long-term Colchicine With Colchicine-resistant Familial Mediterranean Fever (FMF) to Evaluate the Efficacy of On-demand Anakinra Treatment for Painful Attacks in Patients Who Refuse Continuous Daily The

Status:
RECRUITING

Trial end date:
2026-12-04

Target enrollment:

Participant gender:

Summary

To evaluate the efficacy on clinical symptoms in case of FMF attack among FMF patients resistant to Colchicine of * on demand anakinra treatment (100 mg/d from the prodromal phase of the attack until 24 hours of remission (during 7 days maximum) associated with daily colchicine. * compared to analgesic associated with daily colchicine in patients refusing continuous anti-IL-1 treatment.

Phase:

PHASE3

Details

Lead Sponsor:

Assistance Publique - Hôpitaux de Paris

Treatments:

Interleukin 1 Receptor Antagonist Protein